The results of these studies suggested that zoledronate effectiveness, in terms of “BM prevention”, could be restricted to women in physiological menopause and those undergoing ovarian suppression, induced by the addition of gonadotropin-releasing hormone agonists to either tamoxifen or aromatase inhibitors in patients with hormone-receptor-positive BC [65], probably attributable to the potentially overlapping bone-protecting effect of estrogens and BPs in fertile age [66]. The gene discussed is CYP19A1; the disease is breast cancer.